- Clone:
- REAL717
- Type of antibody:
- Releasable fluorochromes, Primary antibodies, Recombinant antibodies
- Applications:
- MICS, IF, IHC Glossary
- Select a conjugate:
Related products for ACPP Antibody, anti-human, REAdye_lease™
A
B
Clone REAL717 is an antibody fragment derived from the full ACPP antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL717 recognizes the human ACPP (acid phosphatase, prostate), also known as PAP (prostatic acid phosphatase. ACPP is a non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions. ACPP has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma. Isoform 2 of ACPP acts as a tumor suppressor of prostate cancer through dephosphorylation of ERBB2 and deactivation of MAPK-mediated signaling. It also generates adenosine from AMP which acts as a pain suppressor.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).
PAP (Prostatic Acid Phosphatase), 5'-NT, Ecto-5'-nucleotidase, TMPase, PAPf39
Technical specifications
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Graddis, T. J. et al. (2011) Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol 4 (3): 295-306
- Veeramani, S. et al. (2005) Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 12 (4): 805-822